(Q37933052)

25 August 2017

1 reference

title

Interfering with pH regulation in tumours as a therapeutic strategy (English)

1 reference

25 August 2017

Dario Neri

0 references

Claudiu T Supuran

1 reference

25 August 2017

publication date

16 September 2011

1 reference

Nature Reviews Drug Discovery

25 August 2017

published in

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

767-777

1 reference

Hallmarks of Cancer: The Next Generation

25 August 2017

cites work

1 reference

Angiogenesis: an organizing principle for drug discovery?

31 March 2020

1 reference

Why do cancers have high aerobic glycolysis?

31 March 2020

1 reference

Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies

31 March 2020

1 reference

Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression

31 March 2020

1 reference

Proton dynamics in cancer

31 March 2020

1 reference

Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion

31 March 2020

1 reference

Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths

31 March 2020

1 reference

The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH.

31 March 2020

1 reference

Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells.

31 March 2020

1 reference

Tumor cell metabolism: cancer's Achilles' heel

31 March 2020

1 reference

Hypoxia signalling in cancer and approaches to enforce tumour regression

31 March 2020

1 reference

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

31 March 2020

1 reference

Carbonic anhydrase inhibitors

31 March 2020

1 reference

V-ATPase inhibitors and implication in cancer treatment.

31 March 2020

1 reference

The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II

31 March 2020

1 reference

Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl-/HCO3- exchanger, AE1.

31 March 2020

1 reference

The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation

31 March 2020

1 reference

Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery

31 March 2020

1 reference

pH control mechanisms of tumor survival and growth

31 March 2020

1 reference

Modulation of carbonic anhydrase activity and its applications in therapy

31 March 2020

1 reference

Carbonic anhydrase inhibitors and activators and their use in therapy

31 March 2020

1 reference

Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets

31 March 2020

1 reference

Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers

31 March 2020

1 reference

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.

31 March 2020

1 reference

Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes.

31 March 2020

1 reference

Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study

31 March 2020

1 reference

The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors

31 March 2020

1 reference

Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX

31 March 2020

1 reference

Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?

31 March 2020

1 reference

Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.

31 March 2020

1 reference

Carbonic anhydrases: current state of the art, therapeutic applications and future prospects

31 March 2020

1 reference

Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.

31 March 2020

1 reference

Targeting tumor-associated carbonic anhydrase IX in cancer therapy

31 March 2020

1 reference

Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.

31 March 2020

1 reference

Carbonic Anhydrase Inhibitors: X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX

31 March 2020

1 reference

Carbonic Anhydrase Inhibitors: Hypoxia-Activatable Sulfonamides Incorporating Disulfide Bonds that Target the Tumor-Associated Isoform IX†

31 March 2020

1 reference

In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives

31 March 2020

1 reference

Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors

31 March 2020

1 reference

Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins

31 March 2020

1 reference

Carbonic Anhydrase Inhibitor Coated Gold Nanoparticles Selectively Inhibit the Tumor-Associated Isoform IX over the Cytosolic Isozymes I and II

31 March 2020

1 reference

Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors

31 March 2020

1 reference

Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model

31 March 2020

1 reference

Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.

31 March 2020

1 reference

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

31 March 2020

1 reference

Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds

31 March 2020

1 reference

Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.

31 March 2020

1 reference

Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation.

31 March 2020

1 reference

7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range

31 March 2020

1 reference

Targeting protein kinases in cancer therapy: a success?

31 March 2020

1 reference

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

31 March 2020

1 reference

Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors

31 March 2020

1 reference

Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII.

31 March 2020

1 reference

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy

31 March 2020

1 reference

31 March 2020

1 reference

Making antibodies by phage display technology

31 March 2020

1 reference

Potent antibody therapeutics by design

31 March 2020

1 reference

Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma

31 March 2020

1 reference

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

31 March 2020

1 reference

Folate-targeted therapeutic and imaging agents for cancer

31 March 2020

1 reference

Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism

31 March 2020

1 reference

Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.

31 March 2020

1 reference

Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1.

31 March 2020

1 reference

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity

31 March 2020

1 reference

The proton-pump inhibitors: similarities and differences

31 March 2020

1 reference

Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells

31 March 2020

1 reference

An intramolecular transport metabolon: fusion of carbonic anhydrase II to the COOH terminus of the Cl(-)/HCO(3)(-)exchanger, AE1

31 March 2020

1 reference

Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters

31 March 2020

1 reference

Identification of the anion exchange protein of Ehrlich cells: a kinetic analysis of the inhibitory effects of 4,4'-diisothiocyano-2,2'-stilbene-disulfonic acid (DIDS) and labeling of membrane proteins with 3H-DIDS.

31 March 2020

1 reference

Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis

31 March 2020

1 reference

Carbonic anhydrase inhibitors

31 March 2020

1 reference

COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents

31 March 2020

1 reference

The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects

31 March 2020

1 reference

Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells.

31 March 2020

1 reference

Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells

31 March 2020

1 reference

Effect of mutations affecting Na+: H+ antiport activity on tumorigenic potential of hamster lung fibroblasts.

31 March 2020

1 reference

Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas

31 March 2020

1 reference

An overview of inhibitors of Na(+)/H(+) exchanger

31 March 2020

1 reference

Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators

31 March 2020

1 reference

Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells.

31 March 2020

1 reference

The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism.

31 March 2020

1 reference

In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH.

31 March 2020

1 reference

Inhibition of the cardiac electrogenic sodium bicarbonate cotransporter reduces ischemic injury

31 March 2020

1 reference

Involvement of AE3 isoform of Na(+)-independent Cl(-)/HCO(3)(-) exchanger in myocardial pH(i) recovery from intracellular alkalization

31 March 2020

1 reference

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

31 March 2020

1 reference

A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo

31 March 2020

1 reference

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

31 March 2020

1 reference

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

31 March 2020

1 reference

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

31 March 2020

1 reference

Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies

31 March 2020

1 reference

Tenascins and the Importance of Adhesion Modulation

31 March 2020

1 reference

Tumour vascular targeting

31 March 2020

1 reference

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody

31 March 2020

1 reference

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

31 March 2020

1 reference

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies

31 March 2020

1 reference

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

31 March 2020

1 reference

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues

31 March 2020

1 reference

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

31 March 2020

1 reference

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

31 March 2020

1 reference

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

31 March 2020

1 reference

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

31 March 2020

1 reference

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

31 March 2020

1 reference

A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer

31 March 2020

1 reference

A proteomic approach for the identification of vascular markers of liver metastasis

31 March 2020

1 reference

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy

31 March 2020

1 reference

Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer

31 March 2020

1 reference

In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations

31 March 2020

1 reference

12 December 2020

Hypoxia-inducible expression of tumor-associated carbonic anhydrases

1 reference

12 December 2020

Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.

1 reference

12 December 2020

Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain

1 reference

12 December 2020

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice

1 reference

12 December 2020

Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment

1 reference

12 December 2020

Antibodies against the cardiac sodium/bicarbonate co-transporter (NBCe1) as pharmacological tools

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3554

1 reference

25 August 2017

1 reference